[go: up one dir, main page]

WO2007006143A1 - Compositions et procédés de détection de cellules transformées - Google Patents

Compositions et procédés de détection de cellules transformées Download PDF

Info

Publication number
WO2007006143A1
WO2007006143A1 PCT/CA2006/001125 CA2006001125W WO2007006143A1 WO 2007006143 A1 WO2007006143 A1 WO 2007006143A1 CA 2006001125 W CA2006001125 W CA 2006001125W WO 2007006143 A1 WO2007006143 A1 WO 2007006143A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
group
alkoxy
halo
compound
Prior art date
Application number
PCT/CA2006/001125
Other languages
English (en)
Inventor
Chaim M. Roifman
Thomas Grunberger
Original Assignee
The Hospital For Sick Children
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Hospital For Sick Children filed Critical The Hospital For Sick Children
Publication of WO2007006143A1 publication Critical patent/WO2007006143A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label

Definitions

  • This invention relates to the use of styrylacrylonitrile compounds for detecting transformed cells.
  • This application relates to diagnostic uses of styrylacrylonitrile compounds, e.g., for detecting cancer, as a consequence of the fluorescent properties of these compounds and their selective uptake by cells that are transformed or otherwise cancerous.
  • compositions for use in detecting cancer comprising such a compound and a physiologically acceptable carrier, diluent, excipient and/or adjuvant.
  • Another embodiment provides a method of detecting and/or assessing the degree of invasiveness of a cancer comprising contacting with a suspected cancer and/or cancer cell with a compound as disclosed herein, followed by detection of the compound.
  • Figure 1 is a histogram comparing the effect of a compound as disclosed herein on cell fluorescence in solid tumour cells versus normal cells.
  • Figure 2 is a histogram showing the effect of a compound as disclosed herein on cell fluorescence in non-solid tumour cells versus normal cells.
  • Figure 3 is a histogram showing the effect that treating normal bone marrow cells with 0 ⁇ M, 25 ⁇ M and 50 ⁇ M of a compound as disclosed herein has on the number of BFU-E, CFU-C and CFU-GEMM colonies on the bone marrow cells.
  • Figure 4 is a histogram demonstrating that enhanced fluorescence of cells treated with a compound as disclosed herein is easily detected up to 18 hours from treatment.
  • Figure 5 is a histogram demonstrating that a compound as disclosed herein is stable in vivo. The presence of a compound as disclosed herein is detected by HPLC of the acetylated derivative of the compound.
  • Cancer cells and cell lines originating from both solid and non-solid tumours selectively uptake, relative to normal (untransformed and/or non-cancerous) cells, certain styryl acrylonitrile compounds as described in greater detail below. Moreover, once in the cancer cells, the fluorescent property of these compounds is enhanced relative to extracellularly located compound. This fortuitous combination of properties enables the detection of cancer and/or cancer cells, which have selectively or preferentially taken up the compound.
  • X is selected from O, S , NH and N-C i -6 alkyl;
  • R 5 is selected from the group consisting OfNH 2 , OH, NH(CH 2 ) p Ar, NH(CH 2 ) p 0H, (CH 2 ) p OC 1-6 alkyl, C 1-6 alkyl, C, -6 aIkoxy, NHNH 2 , NHC(O)NH 2 , NHC(O)C 1-6 alkoxy, N- mo ⁇ holino, and N-pyrrolidino;
  • Ar is an aromatic or heteroaromatic group, unsubstituted or substituted with 1-4 substituents, independently selected from the group consisting of OH, C 1-6 alkyl, Ci -6 alkoxy, NH 2 , NH-Ci -6 alkyl, N(C ]-6 alkyl)(Ci -6 alkyl), and SH,
  • suitable compounds include compounds of Formula II or a salt, solvate, or hydrate thereof
  • Ar is an aromatic or heteroaromatic group, unsubstituted or substituted with 1-4 substituents, independently selected from the group consisting of OH, Ci -6 alkyl, Q-ealkoxy, NH 2 , NH-C 1-6 alkyl, N(Ci -6 alkyl)(C 1-6 alkyl), SH, S-Ci -6 alkyl, NO 2 , CF 3 , OCF 3 , and halo;
  • R 6 is selected from the group consisting of Ar, OH, and OCi -6 alkyl; X is selected from O and S; n is 0-4; and p is 1-4.
  • Ar is an aromatic or heteroaromatic group, unsubstituted or substituted with 1-4 substituents, independently selected from the group consisting of OH, C 1-6 alkyl, C 1-6 alkoxy, NH 2 , NH-C 1-6 alkyl, N(C 1-6 alkyl)(C 1-6 alkyl), SH, S-C 1-6 alkyl, NO 2 , CF 3 , OCF 3 , and halo;
  • R 7 is selected from the group consisting of OH, NH 2 , and OC 1-6 alkyl; X is selected from O and S; and n is 0-4.
  • compounds suitable for use in the subject methods include compounds of Formula IV or a salt, solvate, or hydrate thereof
  • R 4 is unsubstituted Ar, or Ar substituted with 1-4 substituents, independently selected from C 1-6 alkyl, C 1-6 alkoxy, and halo;
  • X is selected from (CH 2 CH 2 O) n and (CH 2 ) n ; and n is 1-4.
  • X is (CH 2 ) n .
  • the present invention also provides compounds of Formula V and salts, solvates, and hydrates thereof
  • R , 4 is Ci -6 alkyl; and n is 1-4.
  • Suitable compounds also include prodrugs of the above compounds.
  • prodrugs will be functional derivatives of a compound of the invention which are readily convertible in vivo into the compound from which it is notionally derived, e.g., by hydrolysis or enzymatic cleavage of a substituent (e.g., of an ester or amide).
  • a substituent e.g., of an ester or amide.
  • Conventional procedures for the selection and preparation of suitable prodrugs are described, for example, in "Design of Prodrugs” ed. H. Bundgaard, Elsevier, 1985.
  • Prodrugs of the compounds of the invention may be conventional esters formed with available hydroxy, amino or carboxyl group.
  • R 1 , R 2 or R 3 when R 1 , R 2 or R 3 is OH in a compound as described herein it may be acylated using an activated acid in the presence of a base, and optionally, in inert solvent (e.g., an acid chloride in pyridine).
  • Some common esters which have been utilized as prodrugs are phenyl esters, aliphatic (C 8 -C 24 ) esters, acyloxymethyl esters, carbamates and amino acid esters.
  • the compound does not demonstrate appreciable toxicity to normal cells at concentrations employed for diagnostic purposes, and/or has high in vivo stability both in living cells and upon intravenous injection in an animal, particularly in a mammal (see, for example, Fig. 3).
  • a compound as set forth above may be advantageously used in in vitro and/or in vivo methods for detecting cancer in cells or animals, particularly mammals, preferably humans.
  • a compound as set forth above may be particularly useful in methods for diagnosing cancer in vivo, methods for detecting metastases, and/or methods for staging of cancer diseases. Such a compound may also be used in selecting treatment options for cancer patients in need thereof.
  • a compound as set forth above may be labelled with radioactive or fluorescent ligands. The selective uptake by cancer cells of such a radioactively or fluorescently labelled compound provides a method for not only detecting cancer and/or cancer cells but also provides a method for assessing the degree of invasiveness of a cancer. In certain embodiments, however, the present invention contemplates the use of compounds that are not radioactive, not fluorescently labelled, or preferably neither radioactive nor fluorescently labelled.
  • the change in the fluorescent property of a compound as set forth above may be obtained even with short-term (1-5 hours) exposure of cells, to the compound and is obtained without specifically labelling the compound with a fluorescent ligand.
  • a compound as set forth above is particularly useful in fluorescence-based detection of cancer and/or cancer cell cells.
  • FACS Fluorescent Activated Cell Sorter
  • selective uptake of a compound as set forth above by cancer cells may permit direct observation of malignancies in vivo.
  • skin cancers e.g., melanoma
  • malignancies of the mouth, throat, stomach, bronchi, colon, prostate and breast may all be directly detected.
  • a compound as set forth above may also be used in vitro to provide an inexpensive, fast, simple and reliable way of detecting malignant cells that does not require special training or equipment and can thus be performed in practically any local hospital facility.
  • a suspected cancer and/or cancer cell may be detected by administering a compound as set forth above, e.g., alone or in a composition comprising the compound, to a site containing the suspected cancer.
  • Administration may be in vivo, ex vivo or in vitro.
  • any excess compound may then be removed or washed off from the site containing the suspected cancer.
  • Detection of the compound may then be performed to determine whether the compound has been selectively taken up by the suspected cancer. The results may be compared against a standard involving known normal cells and a conclusion drawn as to whether the suspected cancer and/or cancer cell is indeed a cancer. Since the fluorescence of the compounds disclosed herein is selectively enhanced in cancer cells, fluorescence-based detection methods may be conveniently used in an assay.
  • detecting fluorescence can be performed by irradiating the cells with light including the excitation wavelength of the compound being used, followed by detection of light emitted by the cells at the emission wavelength of the compound.
  • a compound's excitation and emission wavelengths can readily be determined using techniques well established in the art.
  • a compound as set forth above may be administered alone or in a composition or formulation comprising the compound and a physiologically acceptable carrier, diluent, excipient and/or adjuvant either in vitro or in vivo to bring the compound into contact with cancer cells.
  • a physiologically acceptable carrier, diluent, excipient and/or adjuvant either in vitro or in vivo to bring the compound into contact with cancer cells.
  • the route of administration and the type of composition or formulation used generally depend on the type of cancer and/or cancer cell being detected and whether the compound is to be used in vitro or in a patient.
  • Formulations comprise the active compound in combination with one or more physiologically acceptable ingredients, such as carriers (including implant carriers or microcapsules), excipients, diluents and/or adjuvants.
  • physiologically acceptable ingredients such as carriers (including implant carriers or microcapsules), excipients, diluents and/or adjuvants.
  • Such ingredients generally refer to inert, non-toxic solid materials that do not react with the active compound of the invention.
  • the active compound may be formulated into a formulation for enteral (e.g., oral), buccal, topical, transdermal (e.g., patch), intranasal, intraperitoneal, ophthalmic, intraocular, parenteral (e.g., intravenous, intraarterial, intramuscular, intrathecal or infusion or subcutaneous), rectal, administration, or in a form suitable for administration by inhalation or insufflation, or another mode of administration.
  • enteral e.g., oral
  • buccal topical
  • transdermal e.g., patch
  • intranasal e.g., intraperitoneal
  • ophthalmic e.g., intraocular
  • parenteral e.g., intravenous, intraarterial, intramuscular, intrathecal or infusion or subcutaneous
  • rectal e.g., administration by inhalation or insufflation, or another mode of administration.
  • Formulations may be prepared, for example, in unit dose forms, such as dragees, tablets, capsules, suppositories or ampoules. They may be prepared in a conventional manner, for example by means of conventional mixing, granulating, confectioning, dissolving or lyophilising processes.
  • the compounds of the present invention may take the form of, for example, granules, tablets, capsules, liquids or dragees prepared together with physiologically acceptable carriers, excipients and/or diluents.
  • physiologically acceptable ingredients include:
  • binding agents such as starch (e.g., pregelatinised maize starch, wheat starch paste, rice starch paste, potato starch paste), polyvinylpyrrolidone, hydroxypropyl methylcellulose, gum tragacanth and/or gelatin;
  • fillers such as sugars (e.g., lactose, saccharose, mannitol, sorbitol), amylopectin, cellulose preparations (e.g., microcrystalline cellulose), calcium phosphates (e.g., tricalcium phosphate, calcium hydrogen phosphatelactose) and/or titanium dioxide;
  • sugars e.g., lactose, saccharose, mannitol, sorbitol
  • amylopectin e.g., microcrystalline cellulose
  • calcium phosphates e.g., tricalcium phosphate, calcium hydrogen phosphatelactose
  • titanium dioxide e.g., titanium dioxide
  • lubricants such as stearic acid, calcium stearate, magnesium stearate, talc, silica, silicic acid, polyethylene glycol and/or waxes;
  • disintegrants such as the above-mentioned starches, carboxymethyl starch, cross-linked polyvinylpyrrolidone, agar, alginic acid or a salt thereof (e.g., sodium alginate) and/or sodium starch glycollate;
  • wetting agents such as sodium lauryl sulphate
  • Soft gelatin capsules may be prepared with capsules containing a mixture of the compound together with paraffin oil, liquid polyethylene glycols, vegetable oil, fat and/or another suitable vehicle for soft gelatin capsules. Plasticizers such as glycerol or sorbitol may also be used. Hard gelatin capsules may contain granules of the compound. Hard gelatin capsules may also contain the compound in combination with solid powdered ingredients such as those listed above. Liquid formulations for oral administration may be prepared in the form of solutions, syrups or suspensions.
  • Liquid formulations typically comprise the compound together with an excipient such as sugar or sugar alcohols, and a carrier such as ethanol, water, glycerol, propylene glycol, polyethylene glycol, almond oil, oily esters or mixtures thereof.
  • a carrier such as ethanol, water, glycerol, propylene glycol, polyethylene glycol, almond oil, oily esters or mixtures thereof.
  • such liquid formulations may also contain coloring agents, flavoring agents, saccharine, thickening agents (e.g., carboxymethyl cellulose), suspending agents (e.g., sorbitol syrup, methyl cellulose, hydrogenated edible fats), emulsifying agents (e.g. lecithin, acacia), and/or preservatives (e.g., methyl p-hydroxybenzoates, propyl p- hydroxybenzoates, sorbic acid).
  • Liquid formulations for oral administration may also be prepared in the form of a dry powder to be re
  • Dragee cores are provided with suitable coatings that may be resistant to gastric juices, there being used, inter alia, concentrated sugar solutions which may contain gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, coating solutions in suitable organic solvents or solvent mixtures, or, for the preparation of enteric coatings, solutions of suitable cellulose preparations, such as acetylcellulose phthalate or hydroxypropylmethylcellulose phthalate. Colourings or pigments may be added to the tablets or dragee coatings, for example for identification purposes or to indicate different doses of active compound.
  • the formulation may take the form of tablets of lozenges formulated in conventional manner.
  • the active compounds of the invention may be formulated for parenteral administration by injection, including using conventional catheterization techniques or infusion.
  • Formulations for injection may be presented in unit dosage form (e.g., in ampoules or in multi-dose containers) with an added preservative.
  • the formulations may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulating agents such as suspending, stabilizing and/or dispersing agents.
  • aqueous solutions of the active compound in water-soluble form for example a water-soluble salt, are particularly suitable for parenteral administration.
  • Suspensions of the active compound are also suitable.
  • Oily injection suspensions using suitable lipophilic solvents or vehicles such as fatty oils (e.g., sesame oil, synthetic fatty acid esters like ethyl oleate or triglycerides) may be used.
  • fatty oils e.g., sesame oil, synthetic fatty acid esters like ethyl oleate or triglycerides
  • Aqueous injection suspensions that contain viscosity- increasing substances for example sodium carboxymethylcellulose, sorbitol and/or dextran and optionally also stabilisers may also be used.
  • the active compound may be in powder form for reconstitution with a suitable vehicle (e.g., sterile pyrogen-free water) before use.
  • Rectally administrable formulations for example, suppositories that comprise a combination of the active compound and a suppository base are also provided.
  • Suitable as suppository bases are, for example, natural or synthetic triglycerides, paraffin hydrocarbons, polyethylene glycols and higher alkanols. It is also possible to use gelatin rectal capsules that comprise a combination of the active compound and a base material.
  • Suitable base materials are, for example, liquid triglycerides, polyethylene glycols and paraffin hydrocarbons.
  • the active compounds of the invention are conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant (e.g., dichlorodifiuoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas).
  • a suitable propellant e.g., dichlorodifiuoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • the pressurized container or nebulizer may contain a solution or suspension of the active compound.
  • Capsules and cartridges for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.
  • a compound as set forth above may be applied or administered at a concentration in a range of about 10 nM to about 50 ⁇ M.
  • the active compound is administered and dosed in accordance with good medical practice, taking into account the clinical condition of the individual animal, the site and method of administration, scheduling of administration, animal age, sex, body weight and other factors known to practitioners.
  • An effective dose of the compound may depend on various factors, such as the method of administration, species of animal, age and/or individual condition.
  • C 1-6 alkyl as used herein means, unless otherwise stated, straight and/or branched chain alkyl radicals containing from one to six carbon atoms and includes methyl, ethyl, propyl, isopropyl, t-butyl and the like.
  • d- ⁇ alkoxy as used herein means, unless otherwise stated, straight and/or branched chain alkoxy radicals containing from one to six carbon atoms and includes methoxy, ethoxy, propyloxy, isopropyloxy, t-butoxy and the like.
  • C 1-4 alkyl as used herein means, unless otherwise stated, straight and/or branched chain alkyl radicals containing from one to four carbon atoms and includes methyl, ethyl, propyl, isopropyl, t-butyl and the like.
  • Ci -4 alkoxy as used herein means, unless otherwise stated, straight and/or branched chain alkoxy radicals containing from one to four carbon atoms and includes methoxy, ethoxy, propyloxy, isopropyloxy, t-butoxy and the like.
  • halo as used herein means halogen and includes chloro, fluoro, bromo, iodo and the like.
  • pharmaceutically acceptable salt means an acid addition salt which is suitable for or compatible with the treatment of patients.
  • pharmaceutically acceptable acid addition salt means any non-toxic organic or inorganic salt of any base compounds represented by Formulae I-V, or their intermediates.
  • Illustrative inorganic acids which form suitable salts include hydrochloric, hydrobromic, sulfuric and phosphoric acids, as well as metal salts such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate.
  • Illustrative organic acids that form suitable salts include mono-, di-, and tricarboxylic acids such as glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, benzoic, phenylacetic, cinnamic and salicylic acids, as well as sulfonic acids such as p- toluenesulfonic and methanesulfonic acids. Either the mono or di-acid salts can be formed, and such salts may exist in either a hydrated, solvated or substantially anhydrous form.
  • mono-, di-, and tricarboxylic acids such as glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, benzoic, phenylacetic, cinnamic and salicylic acids, as well as sulf
  • the acid addition salts of compounds as set forth herein are more soluble in water and various hydrophilic organic solvents, and generally demonstrate higher melting points in comparison to their free base forms.
  • the selection of the appropriate salt will be known to one skilled in the art.
  • Other non-pharmaceutically acceptable salts e.g. oxalates, may be used, for example, in the isolation of compounds of Formulae I- V for laboratory use, or for subsequent conversion to a pharmaceutically acceptable acid addition salt.
  • solvate means a compound of Formulae I- V, or a pharmaceutically acceptable salt of a compound of Formulae I- V, wherein molecules of a suitable solvent are incorporated in the crystal lattice.
  • a suitable solvent is physiologically tolerable at the dosage administered. Examples of suitable solvents are ethanol, water and the like. When water is the solvent, the molecule is referred to as a "hydrate”.
  • an "effective amount” or a "sufficient amount " of an agent as used herein is that amount sufficient to effect beneficial or desired results, including clinical results, and, as such, an "effective amount” depends upon the context in which it is being applied and would be understood by a person skilled in the art.
  • an effective amount of an agent is, for example, an amount sufficient to achieve such a modulation in cell proliferation as compared to the response obtained without administration of the agent.
  • animal as used herein includes all members of the animal kingdom including human.
  • the animal is preferably a human.
  • a cell as used herein includes a plurality of cells. Administering a compound to a cell includes in vivo, ex vivo and in vitro administration.
  • Example CR4 ((E,E)-2-(Benzylaminocarbonyl)-3-(3,4- dihydroxystyryl)acrylonitrile) may be prepared by methods described in WO 01/79158. The synthesis is described below.
  • the compound was prepared as described in Example A 1 by adding methyl cyanoacetate (1.3 mL, 14 mmol) to benzylamine (1.5 mL, 14 mmol). The compound was distilled in vacuo directly from the reaction mixture (Kugelrohr apparatus (Aldrich), 0.1 mm Hg, T. oven 180-190 °C) to give an off-white solid (2.34 g, 95%).
  • Example A 7 The compound was prepared as described in Example CRl 1, by adding 3,4- dimethoxycinnamaldehyde (Example A 7 , 0.04 g, 0.2 mmol) to N-(cyanoacetyl)benzylamide (Example A 3 , 0.036 g, 0.2 mmol). After refluxing for 1 h and recrystallization from ethanol a yellow solid was obtained (0.045 g, 62%).
  • Example A 8 Methyl ester of 3,4-bis(t-butyldimethylsilyloxy)cinnamic acid (A 8 )
  • Example A 9 The compound was prepared as described in Example A 6 by treating of 3,4- dihydroxycinnamic acid bis(BDMS) ether methyl ester (Example A 9 , 0.42 g, 1.0 mmol) with IM THF solution of diisobutylaluminum hydride (4.0 mmol) in absolute THF (25 mL) at 2O 0 C for 1 h. After distilling in vacuo (Kugelrohr apparatus (Aldrich), 0.1 mm Hg, T. oven 185-200 0 C) a white viscous oil was obtained, yield 0.33 g (85%).
  • Example A 10 3,4-Bis(t-butyldimethylsilyloxy)cinnamaldehyde (Ai 0 )
  • Example A 7 The compound was prepared as described in Example A 7 by adding 3,4-bis(t- butyldimethylsilyloxy)cinnamyl alcohol (Example A 9 , 0.2 g, 0.5 mmol) in 5 mL Of CH 2 Cl 2 to a mixture of pyridinium dichromate (0.38 g, 1 mmol) and 1 g molecular sieves 3 A in 20 mL OfCH 2 Cl 2 . The residue was passed through silica gel and washed with 300 mL of EtOAc-hexane, 1 :1. After evaporation the compound was purified by silica gel chromatography (hexane-EtOAc, 5:1) to provide an oil (0.15 g, 76%).
  • Example A 10 The compound was prepared as described in Example CRl 1 by adding 3,4-bis(Y- butyldimethylsilyloxy) cinnamaldehyde (Example A 10 , 0.100 g, 0.26 mmol) to N- (cyanoacetyl)benzylamide (Example A 3 , 0.044 g, 0.26 mmol. After refluxing for 2.5 h purification by silica gel chromatography (hexane-EtOAc, 15:1) provided a yellow solid (0.090 g, 64%).
  • Example 1 The fluorescence of compound of formula (I) is enhanced in solid tumor cells, but not normal cells.
  • Normal human fibroblasts or transformed human embryonic kidney cells or various human cancer cells were cultured in an appropriate medium with 10% FCS.
  • Subconfluent cell cultures were incubated in complete medium with or without 50 ⁇ M of CR4.
  • the cells were incubated with the compound for 2.5 hours at 37 °C under 5% CO 2 . At the end of this period, the cells were thoroughly washed in medium to remove CR4, detached and analysed by flow cytometry.
  • the results are shown in Figure 1. The results demonstrate that the fluorescence CR4 is enhanced in solid tumor cancer cells, but not normal cells.
  • Example 2 The fluorescence of CR4 is specifically enhanced in non-solid human cancer cells.
  • Example 3 Treatment of normal bone marrow with high dose of CR4 does not demonstrate toxicity of the compound.
  • Bone marrow cells were layered over PercollTM and centrifuged at 400 g at 4 0 C for 10 minutes to remove neutrophils and red blood cells (RBCs). The cells were resuspended at lxlO 6 /mL in complete medium with or without 50 ⁇ M of CR4. The cells were incubated with the compound for 2.5 hours at 37 0 C under 5% CO 2 .
  • the cells were thoroughly washed in medium to remove CR4 and then cultured at 2x10 5 cells/mL in IMDM containing 0.9% (v/v) methylcellulose supplemented with 30% FCS or normal human plasma, and a cocktail of cytokines, containing G-CSF (10 ng/mL), IL-3 (40 LVmL), MGF (50 ng/mL), Erythropoietin (2 LVmL) or TPO (10 ng/mL) and 5xlO- 5 M ⁇ -2- mercaptoethanol.
  • the culture mixture was plated in 1 mL volumes into 35 mL dishes and incubated at 37 0 C under 5% CO 2 in a humidified atmosphere.
  • BFU-B colonies defined as aggregates of more than 500 hemaglobinized eels or 3 or more erythroid subcolonies
  • CFU-C colonies defined as granulocyte or monocyte-macrophage cells or both
  • CFU-GEMM colonies a mixed population comprising of all elements.
  • CR4 displayed negligible toxicity upon normal bone marrow at doses up to 50 ⁇ M, as illustrated in Figure 3.
  • Example 4 CR4 is stable in living cells. Cl pre-B ALL cells were treated with 50 ⁇ M of CR4 as in Example 2, washed, incubated in the absence of the compound in complete medium at 37 0 C for time periods indicated in Figure 4, and analysed by flowcytometry. Increased fluorescence in cells treated with CR4 but not in control cells was easily detected even upon 18 hours of incubation free from the compound. The results are illustrated in Figure 4.
  • Example 5 CR4 is stable in vivo.
  • mice Nine week old BALBc mice were injected intravenously with 100 ⁇ M of CR4 in 250 ⁇ L of 0.1% DMSO, or, with 250 ⁇ L of 0.1% DMSO alone. Blood samples were taken after the time periods indicated in Figure 5, plasma was prepared and analysed by HPLC.
  • the 3,4-diacetate derivative was prepared by treating CR4 (10 mg, 31.3 ⁇ mol) with 70 ⁇ L of pyridine and 70 ⁇ L of acetic anhydride at 20 0 C for 1 hour:
  • HPLC analyses were performed on a WatersTM 600 chromatograph (USA) with a PDA detector using a Nova-PakTM C18 3.9x300 mm column (WatersTM, USA), with 60:40 MeCN-H 2 O as eluent, at a flow rate of 1.0 mL/min and detecting at a UV wavelength of 340 nm.
  • the compound standard showed a peak at RT 8.9 min, ⁇ max 338 nm.
  • the plasma samples were taken to dryness by evaporating water with acetonitrile and derivatized with 200 ⁇ L pyridine and 200 ⁇ L acetic anhydride at 2O 0 C for 12 hours.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne l’utilisation de composés styryle acrylonitrile fluorescents sélectivement absorbés par des cellules cancéreuses par rapport à des cellules normales. Les propriétés fluorescentes de ces composés sont traitées dans les cellules cancéreuses. De tels composés peuvent être utilisés pour la détection de cancer et/ou de cellules transformées à la fois in vitro et in vivo.
PCT/CA2006/001125 2005-07-13 2006-07-10 Compositions et procédés de détection de cellules transformées WO2007006143A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69901205P 2005-07-13 2005-07-13
US60/699,012 2005-07-13

Publications (1)

Publication Number Publication Date
WO2007006143A1 true WO2007006143A1 (fr) 2007-01-18

Family

ID=37636704

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2006/001125 WO2007006143A1 (fr) 2005-07-13 2006-07-10 Compositions et procédés de détection de cellules transformées

Country Status (1)

Country Link
WO (1) WO2007006143A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010005807A3 (fr) * 2008-07-08 2010-03-25 Board Of Regents, The University Of Texas System Nouveaux inhibiteurs de la prolifération et d'activation du transducteur de signaux et activateur de la transcription (stats)
CN103018463A (zh) * 2012-12-20 2013-04-03 北京大学人民医院 检测急性b淋巴细胞白血病相关免疫表型的试剂盒及其应用
US8450337B2 (en) 2008-09-30 2013-05-28 Moleculin, Llc Methods of treating skin disorders with caffeic acid analogs
US11593369B2 (en) 2010-01-15 2023-02-28 Ab Initio Technology Llc Managing data queries

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6190877B1 (en) * 1999-12-27 2001-02-20 Edwin L. Adair Method of cancer screening primarily utilizing non-invasive cell collection and fluorescence detection techniques
WO2003062190A1 (fr) * 2002-01-18 2003-07-31 The Hospital For Sick Children Composes destines a moduler la proliferation cellulaire
US6617458B2 (en) * 2000-07-08 2003-09-09 Spyros Theodoropulos Alpha cyano methine and polymethine dyes for the labeling of biological subtrates
US6800659B2 (en) * 2000-04-13 2004-10-05 Hsc Research And Development Limited Partnership Compounds for modulating cell proliferation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6190877B1 (en) * 1999-12-27 2001-02-20 Edwin L. Adair Method of cancer screening primarily utilizing non-invasive cell collection and fluorescence detection techniques
US6800659B2 (en) * 2000-04-13 2004-10-05 Hsc Research And Development Limited Partnership Compounds for modulating cell proliferation
US6617458B2 (en) * 2000-07-08 2003-09-09 Spyros Theodoropulos Alpha cyano methine and polymethine dyes for the labeling of biological subtrates
WO2003062190A1 (fr) * 2002-01-18 2003-07-31 The Hospital For Sick Children Composes destines a moduler la proliferation cellulaire

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"FM Lipophilic Styryl Dyes", MOLECULAR PROBES (INVITROGEN LTD.), 17 May 2005 (2005-05-17), XP003007027, Retrieved from the Internet <URL:http://www.probes.invitrogen.com/media/pis/mp34653.pdf> *
DEMIN P. ET AL.: "Tyrenes: synthesis of new antiproliferative compounds with an extended conjugation", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 12, 2004, pages 3019 - 3026, XP003007028 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010005807A3 (fr) * 2008-07-08 2010-03-25 Board Of Regents, The University Of Texas System Nouveaux inhibiteurs de la prolifération et d'activation du transducteur de signaux et activateur de la transcription (stats)
CN102143947A (zh) * 2008-07-08 2011-08-03 得克萨斯系统大学评议会 增殖和信号转导及转录激活蛋白激活的新抑制剂
JP2011527679A (ja) * 2008-07-08 2011-11-04 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム シグナル伝達性転写因子（ｓｔａｔ）の増殖及び活性化の新規の抑制剤
US8143412B2 (en) 2008-07-08 2012-03-27 Board Of Regents, The University Of Texas System Inhibitors of proliferation and activation of signal transducer and activator of transcription (STATs)
US8637675B2 (en) 2008-07-08 2014-01-28 Board Of Regents, The University Of Texas System Inhibitors of proliferation and activation of signal transducer and activators of transcription (STATS)
AU2009268841B2 (en) * 2008-07-08 2014-02-06 Board Of Regents, The University Of Texas System Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (STATS)
EA020766B1 (ru) * 2008-07-08 2015-01-30 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Ингибиторы пролиферации и активации переносчика сигнала и активатора транскрипции (stats)
US9000179B2 (en) 2008-07-08 2015-04-07 Board Of Regents, The University Of Texas System Inhibitors of proliferation and activation of signal transducer and activator of transcription (STATs)
CN102143947B (zh) * 2008-07-08 2015-06-24 得克萨斯系统大学评议会 增殖和信号转导及转录激活蛋白激活的新抑制剂
US8450337B2 (en) 2008-09-30 2013-05-28 Moleculin, Llc Methods of treating skin disorders with caffeic acid analogs
US11593369B2 (en) 2010-01-15 2023-02-28 Ab Initio Technology Llc Managing data queries
CN103018463A (zh) * 2012-12-20 2013-04-03 北京大学人民医院 检测急性b淋巴细胞白血病相关免疫表型的试剂盒及其应用

Similar Documents

Publication Publication Date Title
JP6779793B2 (ja) リンパ腫を治療するためのｅｚｈ２阻害剤
CN108349958B (zh) 用ezh2抑制剂治疗mrto/sccoht的方法
JP5662564B2 (ja) アリールアミノプリン誘導体、その調製方法および医薬としての使用
CN104363913A (zh) Cdk8/cdk19选择性抑制剂及其在癌症的抗转移和化学预防方法中的用途
CA3160899C (fr) Compose spiro servant d&#39;inhibiteur d&#39;erk et son application
WO2020142413A1 (fr) Compositions et procédés de modulation de la pousse des cheveux
CN104136020B (zh) 重编程效应蛋白相互作用以纠正癌症中的表观遗传缺陷
WO2007006143A1 (fr) Compositions et procédés de détection de cellules transformées
US11103603B2 (en) 18F-labeled compounds for PET imaging and uses thereof
Duan et al. Synthesis, anticancer activity, and molecular docking of New 1, 2, 3-Triazole linked tetrahydrocurcumin derivatives
KR101975299B1 (ko) 인돌아세트산의 코어구조를 함유하는 화합물 및 그의 용도
KR101789934B1 (ko) 상피세포성장인자수용체 변이체를 가진 종양 진단 및 종양 성장 억제 활성을 갖는 신규 화합물 및 이를 포함하는 의학적 용도
AU2019265011B2 (en) Inhibitors of the RAS oncoprotein, methods of making and methods of use thereof
CN104169277B (zh) 极光激酶和flt3激酶调节剂
KR102470980B1 (ko) Egfr 및 erbb2에 작용하는 피리미딘계 화합물
JP2017511348A (ja) Ｂｃｒ−Ａｂｌ二倍体の阻害剤、その調製方法及びその用途
AU2011274194B2 (en) Phenyl nitrone compounds containing stilbene segment and use thereof
ES2662917T3 (es) Compuestos de quinona y sus usos para el tratamiento del cáncer
Khaliullin et al. Synthesis and antidepressant activity of 2-bromo-1-(thietan-3-yl)-imidazole-4, 5-dicarboxylic acid derivatives
RU2295517C1 (ru) Производные дикарбоновых кислот, ингибиторы метастазов и средства, повышающие химиотерапевтическую активность противоопухолевых препаратов, способ усиления эффективности цитостатиков, способ ингибирования процесса метастазирования
WO2022271540A1 (fr) Inhibiteurs de dot1l
CN107001258B (zh) 作为用于治疗癌症的治疗剂的4-氧代-n-(4-羟基苯基)视黄酰胺衍生物
CN118986992A (zh) 一种哌啶羧酸酯类化合物在制备恶性肿瘤药物中的应用
JP2021525809A (ja) プロドラッグおよびその医学的使用
NZ727108B2 (en) Ezh2 inhibitors for treating lymphoma

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06752890

Country of ref document: EP

Kind code of ref document: A1